BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38660668)

  • 1. Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy: A case report and review of literature.
    Chu JH; Huang LY; Wang YR; Li J; Han SL; Xi H; Gao WX; Cui YY; Qian MP
    World J Gastrointest Oncol; 2024 Apr; 16(4):1647-1659. PubMed ID: 38660668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody followed by simultaneous transcatheter arterial chemoembolization, and portal vein embolization.
    Luo X; Chang RZ; Kuang D; Yuan M; Li GX; Zhang B; Wang YJ; Zhang WG; Ding ZY
    Front Immunol; 2023; 14():1285296. PubMed ID: 37928536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.
    Kosaka Y; Kawaoka T; Aikata H; Suehiro Y; Yamaoka K; Ando Y; Namba M; Takeuchi Y; Fujii Y; Uchikawa S; Kodama K; Oya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Kimura T; Nagata Y; Chayama K
    Clin J Gastroenterol; 2020 Oct; 13(5):839-843. PubMed ID: 31974811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib for conversion therapy of colorectal cancer liver metastases.
    Peng K; Li Y; Su H; Lan C; Huang Z; Wei Y; Liao X; Peng M; Peng T; Zhu G
    Front Immunol; 2023; 14():1325445. PubMed ID: 38173715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy.
    Wei YG; Su H; Lv ZL; Liao XW; Zeng ZM; Jia YX; Huang HS; Shen XQ; Zhu GZ; Han CY; Ye XP; Peng T
    Front Oncol; 2023; 13():1165538. PubMed ID: 37469401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy.
    Ohya Y; Hayashida S; Tsuji A; Kuramoto K; Shibata H; Setoyama H; Hayashi H; Kuriwaki K; Sasaki M; Iizaka M; Nakahara O; Inomata Y
    Surg Case Rep; 2020 Dec; 6(1):318. PubMed ID: 33301055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
    Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
    J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report.
    Takahashi K; Kim J; Takahashi A; Hashimoto S; Doi M; Furuya K; Hashimoto R; Owada Y; Ogawa K; Ohara Y; Akashi Y; Hisakura K; Enomoto T; Shimomura O; Noguchi M; Oda T
    World J Hepatol; 2021 Mar; 13(3):384-392. PubMed ID: 33815680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoembolization.
    Endo K; Kuroda H; Abe T; Sato H; Kooka Y; Oikawa T; Sato A; Nishiya M; Sugai T; Takikawa Y
    Hepatol Res; 2021 Oct; 51(10):1082-1086. PubMed ID: 33982336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma.
    Chen K; Luo CP; Ge DX; Wang KL; Luo Q; Li YZ; You XM; Xiang BD; Li LQ; Ma L; Zhong JH
    Front Oncol; 2022; 12():946693. PubMed ID: 36276151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
    Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X
    Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
    Wu Z; Gao J; Zhuang W; Yang J; Guo W
    J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic arterial infusion chemotherapy with implantable arterial access port for advanced-stage hepatocellular carcinoma: a case report.
    Jiang X; Aljbri A; Liu J; Shang L; Tian Y; Shao H
    Front Oncol; 2024; 14():1401882. PubMed ID: 38817896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving complete remission in metastatic hepatocellular carcinoma with sintilimab plus sorafenib therapy followed by hepatic resection: a case report.
    Cui K; Li Z; Zhong J; Shi X; Zhao L; Li H; Ma Y
    Front Oncol; 2024; 14():1355798. PubMed ID: 38380371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma.
    Feng X; Feng GY; Tao J; Ao YP; Wu XH; Qi SG; Shi ZR
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10505-10518. PubMed ID: 37284841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatocellular Carcinoma with Vp3 Tumor Thrombosis Treated with Multidisciplinary Treatment--Report of Two Cases].
    Mun Y; Yoshidome H; Shinmura K; Nishida T; Sato Y; Nakamura J; Kato K; Oki A; Sasaki S; Miyazaki M
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1851-3. PubMed ID: 26805194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis.
    Leung JH; Wang SY; Leung HWC; Chan ALF
    Front Oncol; 2024; 14():1344798. PubMed ID: 38434681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of Vp4 hepatocellular carcinoma with tumor thrombosis extending into the confluence of the splenic/portal vein achieved a good prognosis with emergent hepatectomy and postoperative adjuvant therapy with lenvatinib.
    Kato H; Asano Y; Ito M; Arakawa S; Shimura M; Koike D; Ochi T; Yasuoka H; Kawai T; Higashiguchi T; Tani H; Kunimura Y; Kondo Y; Nagata H; Sato H; Horiguchi A
    World J Surg Oncol; 2022 Sep; 20(1):278. PubMed ID: 36057621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
    Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.